跳至主要内容
临床试验/NCT06455488
NCT06455488招募中不适用

MANAGEment of Ventricular Tachycardia Outcomes Registry

CorVita Science Foundation1 个研究点 分布在 1 个国家目标入组 130 人开始时间: 2020年7月20日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
130
试验地点
1
主要终点
Number of Participants with Risk of Sudden Cardiac Death

研究概览

简要总结

Data collection registry for patients with ventricular tachycardia to help physicians give better care for patients clinically and procedurally.

详细描述

After consent from a patient the research team will input patients data from many different categories. There is a link to the PDF for the consent form, a patients anticoagulant medications will be assessed, their ventricular tachycardia (VT) history will be inputted, and their date of birth and zip code will inputted. The research team will then input any EKG's, echocardiograms, VT ablations, ICD's, S-ICD's, lab results, and comorbidities.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Must be at least 18 years old
  • Must not be

排除标准

  • 未提供

研究组 & 干预措施

MANAGE-VT Patients

Patients will be assessed on the status of their ventricular tachycardia as well as other criteria such as: EKG,

干预措施: Ventricular Tachycardia Ablation (Procedure)

MANAGE-VT Patients

Patients will be assessed on the status of their ventricular tachycardia as well as other criteria such as: EKG,

干预措施: ICD Implant (Device)

MANAGE-VT Patients

Patients will be assessed on the status of their ventricular tachycardia as well as other criteria such as: EKG,

干预措施: Antiarrhythmic drug (Drug)

MANAGE-VT Patients

Patients will be assessed on the status of their ventricular tachycardia as well as other criteria such as: EKG,

干预措施: EKG (Diagnostic Test)

MANAGE-VT Patients

Patients will be assessed on the status of their ventricular tachycardia as well as other criteria such as: EKG,

干预措施: Cardioversion (Diagnostic Test)

MANAGE-VT Patients

Patients will be assessed on the status of their ventricular tachycardia as well as other criteria such as: EKG,

干预措施: Echocardiogram (Diagnostic Test)

结局指标

主要结局

Number of Participants with Risk of Sudden Cardiac Death

时间窗: July 20, 2020 - Present

All events of sudden cardiac death that arise from patients with ventricular tachycardia

Recurrence of Ventricular Tachycardia

时间窗: July 20, 2020 - Present

The natural progression of v-tach will be assessed through medical record review

Prevent Risk of Stroke

时间窗: July 20, 2020 - Present

All strokes, transient ischemic and systemic thrombo-embolic events

次要结局

未报告次要终点

研究者

发起方
CorVita Science Foundation
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验